If you have seen documentation on that I will believe. I was told dosing is a safety issue established in the phase 2 realm. If there is no 4 dose precedent, perhaps that is the reason for FDA decline. You know more about trials than I do but, I was told company and CRO design trial and present to FDA and react to FDA response. I am told NP is asking FDA to TELL Cydy how to do trials. That is not how it works and that is where credibility was lost.
Market Data 
Markets 
